The amendment could eliminate the provisions of the bill,
and their associated fiscal impact,
if a particular delivery system for medical marijuana is approved by the federal Food and Drug Administration. This delivery system,
Sativex,
is currently being tested. It is unknown when,
and if,
the U.S. FDA will approve Sativex.

The preceding Fiscal Impact statement is prepared for the benefit of the members of the General Assembly,
solely for the purposes of information,
summarization and explanation and does not represent the intent of the General Assembly or either chamber thereof for any purpose.